Pulmonary vein isolation using the second-generation cryoballoon significantly improved 1-year arrhythmia-free survival compared to the first-generation balloon (83.6% vs 63.9%; P=0.008).
Cohort (n=105)
Does pulmonary vein isolation using the second-generation cryoballoon improve arrhythmia-free survival compared to the first-generation cryoballoon in patients with paroxysmal atrial fibrillation?
The second-generation cryoballoon significantly improves 1-year arrhythmia-free survival compared to the first-generation device in patients undergoing pulmonary vein isolation for paroxysmal atrial fibrillation.
Tasa de eventos absoluta: 83.6% vs 63.9%
valor p: p=0.008
BACKGROUND: The second-generation cryoballoon (CB2) has recently been introduced featuring improved surface cooling. Increased procedural efficacy of pulmonary vein isolation (PVI) when compared to the first-generation balloon (CB1) has been reported. The aim of the study was to investigate the clinical outcome of cryoballoon PVI after 1 year using the CB2 as compared to the CB1. METHODS AND RESULTS: A total of 105 consecutive patients with paroxysmal atrial fibrillation (AF) were studied. Cryoballoon PVI (28 mm) was performed in 50 patients using the CB1, and in 55 patients using the CB2. Patients were scheduled for 72-hour Holter ECG recording at 3, 6, 9, and 12 months and every 6 months thereafter. The study endpoint was defined as recurrent AF or atrial tachycardia >30 seconds documented after a blanking period of 90 days after the procedure. Complete PVI was achieved in 49/50 (98%) and 55/55 (100%) patients in the CB1 and CB2 group, respectively. After a mean follow-up of 416 ± 75 days, 21 (CB1 group) and 10 (CB2 group) patients reached the study endpoint. Kaplan-Meier estimates of arrhythmia-free survival after a single procedure without AAD therapy after 1 year were 63.9% versus 83.6% (P = 0.008) in the CB1 and CB2 group, respectively. Persistent phrenic nerve palsy with delayed healing occurred in 2 (CB1 group) and 3 (CB2 group) patients. CONCLUSION: Clinical outcome of PVI using the CB2 was significantly improved when compared to the CB1.
Fürnkranz et al. (Fri,) conducted a cohort in Paroxysmal atrial fibrillation (n=105). Second-generation cryoballoon (CB2) vs. First-generation cryoballoon (CB1) was evaluated on Recurrent AF or atrial tachycardia >30 seconds documented after a blanking period of 90 days after the procedure (p=0.008). Pulmonary vein isolation using the second-generation cryoballoon significantly improved 1-year arrhythmia-free survival compared to the first-generation balloon (83.6% vs 63.9%; P=0.008).